Teva’s new chief executive Richard Francis ... offered by the NHS in England once again after it was withdrawn from sale in 2021 due to quality issues. Join the conversation, on Tuesday 28th ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback